Jeff Galvin is the CEO and Founder of American Gene Technologies®. He earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT™ after meeting Roscoe Brady at NIH.
New Company | At the beginning of June, American Gene Technologies launched a new company, Addimmune. Please explain the rationale for the spinoff.
Milestones | What is the status of the clinical milestones? https://www.addimmune.com/investors/
Technology | Can you explain the technology that you have developed?
Cure | Is the solution a cure or treatment?
Patents | Can you tell us about your patent portfolio?
Team | Who are the other members of the team? Jeff Boyle, Chief Science Officer, Marcus Conant, Chief Medical Officer
Funding | Are you working on a Series A?